Caraco Pharmaceutical Laboratories Ltd (CPD)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Caraco Pharmaceutical Laboratories Ltd (CPD) with AI Score 46/100 (Weak). Caraco Pharmaceutical Laboratories Ltd. is a healthcare company focused on developing, manufacturing, and distributing generic pharmaceutical products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Caraco Pharmaceutical Laboratories Ltd (CPD) Healthcare & Pipeline Overview
Caraco Pharmaceutical Laboratories Ltd., operating within the Medical - Pharmaceuticals sector, focuses on developing and distributing generic drugs. The company faces competition from larger pharmaceutical firms and must navigate regulatory hurdles and pricing pressures to maintain its market position and profitability within the healthcare industry.
Investment Thesis
Investing in Caraco Pharmaceutical Laboratories Ltd. involves considering the dynamics of the generic pharmaceutical market. The company's ability to efficiently develop, manufacture, and distribute generic drugs is a key value driver. Growth catalysts include successful product launches and expansion into new markets. However, potential risks include increased competition, regulatory challenges, and pricing pressures. Monitoring the company's financial performance, including revenue growth and profitability, is crucial for assessing its investment potential. Investors should also consider the company's ability to manage its debt and maintain a strong balance sheet. The beta of 2.14 indicates higher volatility compared to the market, suggesting a riskier investment profile.
Based on FMP financials and quantitative analysis
Key Highlights
- Caraco Pharmaceutical Laboratories Ltd. operates in the generic pharmaceutical sector, focusing on developing and distributing affordable medications.
- The company's success is tied to its ability to navigate regulatory hurdles and pricing pressures within the competitive pharmaceutical landscape.
- Caraco's product portfolio consists of a range of generic drugs addressing various therapeutic areas.
- The company's geographic reach is primarily within the United States.
- With a beta of 2.14, CPD exhibits higher volatility compared to the overall market.
Strengths
- Expertise in generic drug development and manufacturing.
- Established distribution network.
- Ability to source APIs at competitive prices.
- Focus on cost-effective manufacturing.
Weaknesses
- Reliance on a limited number of products.
- Vulnerability to pricing pressures from competitors.
- Dependence on third-party manufacturers for some products.
- Limited brand recognition.
Catalysts
- Potential FDA approvals for new generic drug applications.
- Expansion of distribution network to reach new markets.
- Strategic partnerships to co-develop and market generic drugs.
Risks
- Increased competition from other generic drug manufacturers.
- Pricing pressures from pharmacy benefit managers (PBMs).
- Changes in regulatory requirements.
- Patent challenges from branded drug manufacturers.
- Supply chain disruptions affecting API sourcing.
Growth Opportunities
- Expansion into New Therapeutic Areas: Caraco Pharmaceutical Laboratories Ltd. can explore opportunities to expand its product portfolio into new therapeutic areas with unmet medical needs. This could involve developing and marketing generic versions of drugs used to treat conditions such as diabetes, cardiovascular diseases, or neurological disorders. The market for these drugs is substantial, with global sales in the billions of dollars. Successful expansion into these areas could significantly increase Caraco's revenue and market share. Timeline: 2-3 years.
- Strategic Partnerships and Acquisitions: Caraco Pharmaceutical Laboratories Ltd. can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This could involve partnering with other pharmaceutical companies to co-develop and market generic drugs, or acquiring smaller companies with complementary product portfolios. Such partnerships and acquisitions could provide Caraco with access to new technologies, markets, and distribution channels. Timeline: 1-2 years.
- Focus on Biosimilars: With the increasing number of biologic drugs facing patent expiration, Caraco Pharmaceutical Laboratories Ltd. can explore opportunities to develop and market biosimilars. Biosimilars are generic versions of biologic drugs, which are complex molecules derived from living organisms. The market for biosimilars is expected to grow significantly in the coming years, driven by the high cost of biologic drugs and the increasing demand for affordable healthcare. Timeline: 3-5 years.
- Geographic Expansion: Caraco Pharmaceutical Laboratories Ltd. can explore opportunities to expand its geographic reach beyond the United States. This could involve entering new markets in Europe, Asia, or Latin America. These markets offer significant growth potential, driven by increasing healthcare spending and growing demand for affordable medications. However, geographic expansion also involves navigating regulatory hurdles and cultural differences. Timeline: 2-4 years.
- Investment in Research and Development: Caraco Pharmaceutical Laboratories Ltd. can invest in research and development to develop new and improved generic drugs. This could involve developing drugs with improved formulations, delivery systems, or therapeutic profiles. Such investments could provide Caraco with a competitive advantage and allow it to capture a larger share of the generic drug market. Timeline: Ongoing.
Opportunities
- Expansion into new therapeutic areas.
- Strategic partnerships and acquisitions.
- Development of biosimilars.
- Geographic expansion into emerging markets.
Threats
- Increased competition from other generic drug manufacturers.
- Pricing pressures from pharmacy benefit managers (PBMs).
- Changes in regulatory requirements.
- Patent challenges from branded drug manufacturers.
Competitive Advantages
- Regulatory expertise in navigating FDA approval processes for generic drugs.
- Established relationships with wholesale distributors and retail pharmacies.
- Efficient manufacturing and supply chain operations.
- Ability to source active pharmaceutical ingredients (APIs) at competitive prices.
About CPD
Caraco Pharmaceutical Laboratories Ltd., headquartered in Detroit, Michigan, is a pharmaceutical company engaged in the development, sourcing, and marketing of generic pharmaceuticals. The company's history involves navigating the complexities of the generic drug market, aiming to provide cost-effective alternatives to branded medications. Caraco focuses on producing and distributing a range of generic drugs addressing various therapeutic areas. These products are sold to wholesalers, distributors, and retailers. The company's geographic reach is primarily within the United States. Caraco faces competition from other generic drug manufacturers, both large multinational corporations and smaller specialized firms. The company's success depends on its ability to efficiently manufacture and distribute its products, navigate regulatory requirements, and manage pricing pressures within the competitive pharmaceutical landscape.
What They Do
- Develop generic pharmaceutical products.
- Manufacture generic drugs.
- Source active pharmaceutical ingredients (APIs).
- Market and distribute generic drugs.
- Sell products to wholesalers, distributors, and retailers.
- Ensure compliance with regulatory requirements.
- Manage supply chain and logistics.
Business Model
- Develop and acquire rights to manufacture generic versions of off-patent drugs.
- Manufacture drugs in-house or through contract manufacturers.
- Distribute and sell drugs through wholesale distributors and retail pharmacies.
- Generate revenue from the sale of generic pharmaceutical products.
Industry Context
Caraco Pharmaceutical Laboratories Ltd. operates within the medical pharmaceutical industry, a sector characterized by intense competition, stringent regulatory oversight, and constant pressure to innovate and reduce costs. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and growing demand for affordable medications. Generic drug manufacturers like Caraco play a crucial role in providing cost-effective alternatives to branded drugs, contributing to healthcare accessibility. The industry is also shaped by patent expirations, which create opportunities for generic drug manufacturers to enter the market. Caraco competes with both large multinational corporations and smaller specialized firms.
Key Customers
- Wholesale drug distributors.
- Retail pharmacy chains.
- Independent pharmacies.
- Hospitals and clinics.
Financials
Chart & Info
Caraco Pharmaceutical Laboratories Ltd (CPD) stock price: Price data unavailable
Latest News
No recent news available for CPD.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CPD.
Price Targets
Wall Street price target analysis for CPD.
MoonshotScore
What does this score mean?
The MoonshotScore rates CPD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
What Investors Ask About Caraco Pharmaceutical Laboratories Ltd (CPD) — Healthcare
What does Caraco Pharmaceutical Laboratories Ltd do?
Caraco Pharmaceutical Laboratories Ltd. is a pharmaceutical company that develops, manufactures, and distributes generic drugs. The company focuses on providing affordable alternatives to branded medications, targeting a range of therapeutic areas. Caraco sells its products to wholesalers, distributors, and retailers, primarily within the United States. The company's success depends on its ability to navigate the competitive generic drug market, manage regulatory requirements, and maintain efficient manufacturing and supply chain operations.
What do analysts say about CPD stock?
AI analysis is pending for Caraco Pharmaceutical Laboratories Ltd., therefore, a summary of analyst consensus, key valuation metrics, and growth considerations is not currently available. Once the AI analysis is complete, a neutral summary of analyst opinions and relevant financial data will be provided. This will include information on analyst ratings, price targets, and key factors influencing the stock's performance.
What are the main risks for CPD?
Caraco Pharmaceutical Laboratories Ltd. faces several risks inherent to the generic pharmaceutical industry. These include intense competition from other generic drug manufacturers, which can lead to pricing pressures and reduced profitability. Regulatory changes and challenges, such as stricter FDA requirements, can also impact the company's operations and increase costs. Additionally, patent challenges from branded drug manufacturers can delay or prevent the launch of new generic drugs. Supply chain disruptions and dependence on third-party manufacturers also pose risks to the company's ability to maintain a consistent supply of products.
What are the key factors to evaluate for CPD?
Caraco Pharmaceutical Laboratories Ltd (CPD) currently holds an AI score of 46/100, indicating low score. Key strength: Expertise in generic drug development and manufacturing. Primary risk to monitor: Increased competition from other generic drug manufacturers. This is not financial advice.
How frequently does CPD data refresh on this page?
CPD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CPD's recent stock price performance?
Recent price movement in Caraco Pharmaceutical Laboratories Ltd (CPD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Expertise in generic drug development and manufacturing. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CPD overvalued or undervalued right now?
Determining whether Caraco Pharmaceutical Laboratories Ltd (CPD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CPD?
Before investing in Caraco Pharmaceutical Laboratories Ltd (CPD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for CPD. Financial data is limited.